Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.

This case study describes a 16-year-old girl with alopecia areata affecting her eyelashes and eyebrows, who showed very limited response to treatment with topical mometasone furoate and subsequent partial hair loss upon stopping the treatment.

A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.

In this retrospective study from North France, apremilast was used in patients with psoriasis and recent cancer, showing a good safety profile and improved quality of life, though with 65.2% experiencing non-serious adverse events. The need for further research on oncological safety was highlighted.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

In this randomized trial, the researchers observed that both montelukast and finasteride effectively reduced acne severity and lesion count in women with moderate acne, but finasteride showed greater efficacy. Both medications had transient, non-serious side effects, indicating satisfactory tolerability and safety.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

This article highlights the potential for latanoprost acid, a metabolite of the glaucoma medication latanoprost, to serve as an effective alternative to current treatments for androgenetic alopecia, such as minoxidil and finasteride, facilitating a faster development process for related drugs.

This case report highlights a rare instance of erosive pustular dermatosis of the scalp in a patient on afatinib, underlining the importance of early recognition and management of this adverse effect.

This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This review discusses emerging evidence on azathioprine's efficacy and safety for severe alopecia areata, reporting sustained response in many patients but emphasizing the need for controlled trials.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.

A woman got a scalp condition from using latanoprost, but it improved after stopping the drug and starting other treatments.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.